---
schema_version: "secwatch.filing_event.v1"
accession: "0000320017-22-000085"
form_type: "8-K"
ticker: "LSTA"
cik: "0000320017"
company_name: "LISATA THERAPEUTICS, INC."
filed_at: "2022-09-22T23:59:59+00:00"
generated_at: "2026-06-23T08:07:26.008494+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lisata halts XOWNA FREEDOM Trial; development now contingent on partner

## Summary
- Phase 2b FREEDOM Trial of XOWNA (autologous CD34+ cells) suspended May 2022 due to COVID enrollment challenges and heterogeneity.
- Interim analysis of first 20 patients with 6-month follow-up completed; board decided redesigned trial is needed but prohibitively expensive alone.
- XOWNA development will only continue if a strategic partner is identified and secured to fund a redesigned trial.
- No assurance that a partner can be found or that acceptable terms will be reached.

## SEC filing metadata
- accession: 0000320017-22-000085
- form_type: 8-K
- ticker: LSTA
- cik: 0000320017
- company_name: LISATA THERAPEUTICS, INC.
- filed_at: 2022-09-22T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/320017/000032001722000085/0000320017-22-000085-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/320017/000032001722000085/clbs-20220922.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000320017-22-000085
- JSON: https://secwatch.observer/filing/0000320017-22-000085.json
- Plain text: https://secwatch.observer/filing/0000320017-22-000085.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.